Clinical Setting Jobs in Princeton, NJ

Location: On-Site 4 days per week at ourPrinceton NJ or Miami FL locationsAbout Summit:Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life increasing potential duration of life and resolving serious unmet medical needs. At Summit we be...

Location: Onsite (Palo Alto CA; Princeton NJ or Miami FL)About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF...

Location: Princeton NJ or Oxford UK onsiteAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molec...

Location: Princeton NJ onsiteAbout Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivone...

Location: US (Princeton NJ) OnsiteReports To: Executive Director Global Commercial Supply ChainAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis eff...

Location: Menlo Park CA; Miami FL; Princeton NJ onsiteAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into...

Location: US (Princeton NJ) OnsiteReports To: Executive Director Global Commercial Supply ChainAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effe...

Location: Menlo Park CA; Miami FL; Princeton NJ (onsite)About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF int...

Location: On-Site 4 days per week at our Menlo Park CA or Princeton NJ office.About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated w...

About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperati...

Location: Princeton NJ (on-site)About Summit:Ivonescimab also known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule....

Location: Princeton NJ onsiteAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonesc...

Location: Princeton NJ (on-site)About Summit: Ivonescimab also known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecul...

Location: Princeton NJ or Oxford UK (on-site)About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single m...

Location: Princeton NJ (on-site)About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivon...

About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperat...

Location: Menlo Park CA Princeton NJ or Miami FL. onsite 4 days per weekAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with bl...